Product Description
Benfotiamine, a synthetic thiamine monophosphate analog with improved bioavailability compared with thiamine, has been shown to prevent the development of microvascular complications in rats without changes in glycemic control (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329837/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Bosnia | Brazil | Bulgaria | Chile | Czech | Egypt | Estonia | Germany | Hong Kong | Hungary | India | Korea | Latvia | Lithuania | Malaysia | Philippines | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | Switzerland | Taiwan | Ukraine | United Arab Emirates | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Wörwag Pharma GmbH & co. KG
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BOND Study | P2 |
Active, not recruiting |
Type 2 Diabetes |
2023-11-27 |